Everolimus
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Everolimus (ncit:C48387)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, HER2-negative | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | TSC1 oncogenic variants | Renal Angiomyolipoma | Everolimus | |
| Sensitivity (+) | TSC2 oncogenic variants | Renal Angiomyolipoma | Everolimus | |
| Sensitivity (+) | TSC1 oncogenic variants | Anaplastic Thyroid Cancer | Everolimus | |
| Sensitivity (+) | TSC2 oncogenic variants | Anaplastic Thyroid Cancer | Everolimus | |
| Sensitivity (+) | ER positive, HER2-negative | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane |